Hemophilia
Drug research and approvals for hemophilia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 88 studies of hemophilia are recruiting on ClinicalTrials.gov, Health Canada has authorized 67 drug trials for it since 2013, FDA has 36 approved and 37 open orphan designations naming it, and the EU has 25 authorised medicines for it.
- Recruiting worldwide: 88
- Trials authorized in Canada: 67
- FDA orphan approvals: 36
- EU medicines: 25
Recruiting Now
Newest start dates first, of 88 recruiting on ClinicalTrials.gov ↗- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenNCT07838194 · Phase 3 · Hoffmann-La Roche · starts Nov 30, 2026
- A Study to Assess the Safety of Marstacimab and How Well it Works in People With Mild to Moderate Hemophilia A or B…NCT07923981 · Phase 3 · Pfizer · starts Oct 23, 2026
- A Research Study Investigating Denecimig (Mim8) in Adults With Acquired Haemophilia ANCT07830732 · Phase 3 · Novo Nordisk A/S · starts Oct 16, 2026
- A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With HemophiliaNCT07681089 · Phase 2 · Kiminori Kimura, MD · starts Oct 1, 2026
- A Prospective Assessment of Bone Health in Patients With Severe Hemophilia A on Factor VIII vs Factor Mimetic…NCT07582276 · Not reported · Arkansas Children's Hospital Research Institute · starts Sep 21, 2026
- A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia ANCT07226206 · Phase 1 / Phase 2 · Hoffmann-La Roche · starts Sep 8, 2026
- Validity and Reliability of the Figure-of-Eight Walking and Weight-Bearing Lunge Tests in HemophiliaNCT07851922 · Not reported · Yuzuncu Yil University · starts Aug 30, 2026
- A First-in Human Study of ARD001 in Healthy Volunteers and People With Hemophilia ANCT07787091 · Phase 1 / Phase 2 · Arditus Pte Ltd · starts Aug 19, 2026
- TG-INSIGHT With Joint POCUS, Hemostatic Potential in Patients With Severe Hemophilia A on Novel Replacement and…NCT07692217 · Not reported · University of Texas Southwestern Medical Center · starts Jul 22, 2026
- An Observational Study to Learn More About How Well Damoctocog Alfa Pegol Works in Children With Hemophilia ANCT07088458 · Not reported · Bayer · starts Jul 16, 2026
Trials Authorized in Canada
The 10 newest of 67; search them all in Canada trials| Aug 18, 2026 | A multicenter, open-label, single-arm, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655) | Roche | Pending |
| Jun 18, 2026 | A multinational, open-label study to investigate efficacy and safety of denecimig (mim8) in adults with acquired haemophilia aMIM8 / NNC0365-3769 | Novo Nordisk | Pending |
| Mar 26, 2026 | A multicenter, randomized, open-label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655) / ELOCTATE / ADYNOVATE / ESPEROCT / XYNTHA / KOVALTRY / JIVI | Roche | Pending |
| Mar 18, 2026 | A multicenter, randomized, open label, phase III clinical trial to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of nxt007 prophylaxis…NXT007 (RO7589655) / HEMLIBRA [EMICIZUMAB (RO5534262)] | Roche | Ongoing |
| Aug 20, 2025 | An open-label, parallel, phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12…FITUSIRAN (SAR439774) | SANOFI-AVENTIS CANADA INC | Ongoing |
| May 9, 2025 | A phase 1 single and multiple dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of sr604 in healthy…SR604 | EQUILIBRA BIOSCIENCE LLC | Closed |
| Feb 27, 2025 | A phase 1 b open-label non-randomized study to assess the safety, pk &pd of marstacimab treatment following the discontinuation of emicizumab therapy in…MARSTACIMAB | Pfizer | Closed |
| Dec 12, 2024 | Synoviiius: prospective interventional study of effectiveness of efanesoctocog alfa prophylaxis on synovial hypertrophy in patients with hemophilia aBIVV001 (EFANESOCTOCOG ALFA) | Sanofi | Ongoing |
| Aug 22, 2024 | A phase 1/2 dose escalation and expansion study of be-101 for the treatment of adults with moderately severe or severe hemophilia bBE-101 | BE BIOPHARMA | Pending |
| Jul 4, 2024 | A phase 3, single-arm, open-label, multicenter study of the safety and efficacy of dirloctocogene samoparvovec (spk-8011, adeno-associated viral vector with…DIRLOCTOCOGENE SAMOPARVOVEC (SPK-8011) / CELLCEPT / METHYLPREDNISOLONE | SPARK THERAPEUTICS INC | Pending |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 73| Jun 5, 2026 | Hympavziroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 6 years of age and older with… | Pfizer Inc. | Approved |
| Jul 31, 2025 | Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Jul 31, 2025 | Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Mar 28, 2025 | Qfitliafor routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older… | Genzyme Corporation | Approved |
| Mar 28, 2025 | Qfitliaroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with… | Genzyme Corporation | Approved |
| Dec 20, 2024 | Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Dec 20, 2024 | Alhemoroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Novo Nordisk, Inc. | Approved |
| Oct 11, 2024 | Hympavziroutine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with… | Pfizer Inc. | Approved |
| Apr 25, 2024 | Beqveztreatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who: Currently use factor IX prophylaxis… | Pfizer Inc. | Approved |
| Jun 29, 2023 | Roctaviantreatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity less than 1 IU/dL) without… | BioMarin Pharmaceutical, Inc. | Approved |
| Feb 22, 2023 | Altuviiioin adults and children with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis to reduce the frequency of bleeding… | Bioverativ Therapeutics, Inc. | Approved |
| Nov 22, 2022 | HemgenixTreatment of adults with Hemophilia B (congenital Factor IX deficiency) who: currently use Factor IX prophylaxis therapy, or; have current… | CSL Behring LLC | Approved |
| Jul 29, 2022 | RebinynRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital Factor IX deficiency) | Novo Nordisk, Inc. | Approved |
| Oct 5, 2021 | BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in adults and children with hemophilia B (congenital factor IX deficiency… | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Approved |
| Jun 26, 2020 | BeneFixRoutine prophylaxis to reduce the frequency of bleeding episodes in patients 16 years of age and older with hemophilia B (congenital factor… | Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc. | Approved |
Medicines Authorised in the EU
Newest first; 15 of 25| Dec 13, 2024 | Alhemoconcizumab | Novo Nordisk A/S | EMA ↗ |
| Nov 18, 2024 | Hympavzimarstacimab | Pfizer Europe MA EEIG | EMA ↗ |
| Jun 17, 2024 | Altuvoctefanesoctocog alfa · orphan | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| Feb 20, 2023 | Hemgenixetranacogene dezaparvovec · orphan | CSL Behring GmbH | EMA ↗ |
| Jul 15, 2022 | Cevenfactaeptacog beta (activated) | Laboratoire Francais du Fractionnement et des Biotechnologies | EMA ↗ |
| Jun 20, 2019 | Esperoctturoctocog alfa pegol | Novo Nordisk A/S | EMA ↗ |
| Nov 22, 2018 | Jividamoctocog alfa pegol | Bayer AG | EMA ↗ |
| Feb 23, 2018 | Hemlibraemicizumab | Roche Registration Limited | EMA ↗ |
| Jan 8, 2018 | Adynovirurioctocog alfa pegol | Baxalta Innovations GmbH | EMA ↗ |
| Jun 2, 2017 | Refixianonacog beta pegol | Novo Nordisk A/S | EMA ↗ |
| Feb 13, 2017 | Vihumasimoctocog alfa | Octapharma AB | EMA ↗ |
| Jan 4, 2017 | Afstylalonoctocog alfa | CSL Behring GmbH | EMA ↗ |
| May 12, 2016 | Alprolixeftrenonacog alfa · orphan | Swedish Orphan Biovitrum AB (publ) | EMA ↗ |
| May 11, 2016 | Idelvionalbutrepenonacog alfa · orphan | CSL Behring GmbH | EMA ↗ |
| Feb 18, 2016 | Kovaltryoctocog alfa | Bayer AG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA